应答指导治疗策略下聚乙二醇干扰素α-2a与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的经济学评价  

Cost-utility Analysis of Peginterferon -2a under RGT Strategy versus Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B

作　　者：范文君[1] 侯金林[2] 江家骥[3] 王贵强[4] 唐小平[5] 赵伟 陈文[1] 

机构地区：[1]复旦大学药物经济学研究与评估中心,复旦大学公共卫生学院,上海200032 [2]广州南方医院,广东广州510515 [3]福建医科大学附属医院,福建福州350005 [4]北京大学第一医院,北京100034 [5]广州市第八人民医院,广东广州510060 [6]南京第二人民医院,江苏南京210000

出　　处：《中国药物经济学》2013年第2期19-22,共4页China Journal of Pharmaceutical Economics

摘　　要：目的在应答指导治疗策略下,对聚乙二醇干扰素α-2a方案与恩替卡韦方案治疗HBeAg阳性的慢性乙型肝炎进行经济学评价。方法运用文献资料和Delphi专家咨询数据,采用Markov模型对使用聚乙二醇干扰素α-2a方案和恩替卡韦方案,比较其直接医疗费用、健康结果和成本效果。结果使用聚乙二醇干扰素α-2a方案治疗HBeAg阳性慢性乙型肝炎,相对恩替卡韦方案,人均延长1.8个质量调整生命年(QALY),人均增加的总治疗费用为18522元,每延长1个QALY所需的医疗费用为10298元。结论在应答指导治疗策略下,使用48周聚乙二醇干扰素α-2a及2年恩替卡韦二线治疗的方案较3年恩替卡韦治疗HBeAg阳性慢性乙型肝炎更具成本效果。Objective The study aimed to evaluate cost-effectiveness of 48 weeks peginterferon a-2a versus entecavir treatment under the Response Guided Therapy （RGT） strategy for HBeAg-positive chronic hepatitis B （CHB）. Methods Based on literature research and Delphi expert survey data, a Markov health-state model was established for economic evaluation of peg-interferon ^-2a compared with entecavir for the treatment of CHB. Results The model showed that peg-interferon ^-2a regimen could prolong 1.8 discounted QALYs with additional 18522 CNY of the total cost per patient, compared with entecavir regimen. The increment.I cost-effectiveness ratio for peginterferon regimen was 10298 CNY per QALY. Conclusion The results of the model suggest that peg-interferon a-2a treatment with and line 2years under RGT is very cost-effective,compared with 3years entecavir for the treatment of CHB.

关 键 词：聚乙二醇干扰素Α-2A 恩替卡韦 慢性乙型肝炎 经济学评价 MARKOV模型 

分 类 号：R956[医药卫生—药学] R512.62